Denali Q2 net loss $99M; FDA open to accelerated approval for DNL310; regains ATV:Abeta rights

Denali Therapeutics Inc.

2024-Q2 EPS reported -$1.26

Net loss $99.0M in Q2 2024 vs $183.4M net income in Q2 2023; no collaboration revenue versus $294.1M last year.
Cash and marketable securities $1.35B as of June 30, 2024.
FDA CDER open to discussing accelerated approval for DNL310 (MPS II) using CSF HS as surrogate biomarker.
Biogen terminated ATV:Abeta license; Denali regains all rights; decision not related to efficacy or safety.
DNL126 (MPS IIIA) selected for FDA START pilot program; Phase 1/2 data expected by end of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.